rb 2

Ginsenoside Rb2 (Ginsenoside C) found in species of Panax, upregulating GPR120 gene expression.

Ginsenoside Rb2 (Standard) is a reference standard for research and analysis in studies involving Ginsenoside Rb2. Ginsenoside Rb2 (Ginsenoside C) found in species of Panax, upregulating GPR120 gene expression.

Ziralimumab (ABX-RB2) is a monoclonal antibody that targets and inhibits IL-2 receptor, thereby modulating the immune response.

RB-CO-PEG5-C2-CO-VH032 is a TRIM24 degrader that can inactivate the mTOR signaling pathway.

Anti-Mouse CD45RB Antibody (MB23G2) is an IgG2a, κ antibody inhibitor derived from rats and targets the mouse CD45RB.

Anti-IL-2Rb/CD122 Antibody is a human-derived antibody expressed in CHO cells, targeting IL-2Rb/CD122. It features a huIgG1 heavy chain and a huλ light chain, with an estimated molecular weight (MW) of 150 kDa. For isotype control, refer to HumanIgG1kappa, Isotype Control.

Anatibant 2HCl is a small molecule bradykinin B2 receptor antagonist for the treatment of neurological disorders and may be used in the study of brain injury.

ARB-272572 is a potent inhibitor of programmed cell death ligand 1 (PD-L1) signaling that induces PD-L1 homodimer interactions and produces immunostimulatory activity in human primary cells.

ARB-272572 hydrochloride is a small molecule PD-L1 inhibitor with an IC50 value of 400 pM for PD-1/PD-L1 HTRF.ARB-272572 hydrochloride inhibits PD-1/PD-L1 cell signaling by inducing homologous interactions with PD-L1 proteins.

FR167344 free base is an orally active, nonpeptide antagonist of the bradykinin receptor B2, exhibiting high-affinity binding (IC50: 65 nM) and showing no binding affinity for the B1 receptor.

ERB-2 is a selective ERβ PROTAC degrader that inhibits the suppression of ROS by ERβ, leading to ROS accumulation, mitochondrial damage, and ultimately causing apoptosis. It significantly suppresses tumor growth in a nude mouse model with NCI-H1975OR tumors and is applicable for research in non-small cell lung cancer.

FR190997 is an agonist of bradykinin B2 receptor.

Labradimil is a bradykinin B2 receptor agonist. Labradimil increases the permeability of human brain microvascular endothelial cell monolayers. Labradimil enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tu

Grb2 SH2 Domain Inhibitor 1 TFA is a cyclic cell-penetrating peptide (CPP) featuring a conformationally restricted d-pro-l-pro motif ring (AF Φ Rpprrfq), where Φ represents L-naphthylalanine, R signifies D-arginine, and P stands for D-proline. It primarily functions as a cyclic peptide inhibitor.

Grb2 SH2 Domain Inhibitor 1 is a cyclic cell-penetrating peptide (CPP) featuring a conformationally restricted d-pro-l-pro motif ring (AF Φ Rpprrfq), where Φ represents L-naphthylalanine, R denotes D-arginine, and P indicates D-proline. This compound primarily functions as a cyclic peptide inhibitor.

PROTAC CDK2 Degrader-1 (Compound 41) is a PROTAC degrader targeting cyclin-dependent kinase 2 (CDK2). It inhibits the phosphorylation of the RB protein in the CDK2-dependent cell line OVCAR3, with an IC50 ranging from 100-500 nM.

AZD8421 is a potent and highly selective inhibitor of cyclin-dependent kinase 2 (CDK2) with an IC50 of 9nM, demonstrating greater selectivity over CDK1, CDK4, and CDK6. This compound also exhibits antiproliferative properties by effectively inhibiting Rb phosphorylation. In models of breast and ovarian cancer, AZD8421 has shown significant activity both as a monotherapy and in combination with CDK4/6 inhibitors.

Amsilarotene (TAC101) inhibits the phosphorylation of retinoblastoma gene product (RB) and increases the presence of 2 cyclin-dependent kinases (CDK) inhibitors resulting in cell cycle arrest. This agent also causes a cytotoxic decline in the thymidylate synthase and cyclin A expression.

TREK1 and TREK2 channel activator (EC50 = 0.76 μM in Rb efflux assay in TREK1-expressing CHO cells). Exhibits selectivity for TREK1/2 over TRAAK, TASK3 and a range of other potassium channels. Hyperpolarizes membrane potential of dorsal root ganglion neurons and depresses neuronal activity in vitro. Loucif et al (2018) GI-530159, a novel, selective, mechanosensitive two-pore-domain potassium (K2P) channel opener, reduces rat dorsal root ganglion neuron excitability. Br.J.Pharmacol. 175 2272 PMID:29150838

1. Schisandrol B (Besigomsin) may exert neuroprotective effects by attenuating the microglia-mediated neuroinflammatory response via inhibiting the TLR4-mediated NF-κB and MAPKs signaling pathways. 2. Schisandrol B has anti-inflammatory property, potentially result from the inhibition of COX-2, iNOS, IL-6, TNF-α and NO through the down-regulation of RIP2 and NF-κB activation. 3. Schisandrol B induces marked protective effects against hepatic and renal injury induced by CCl(4) exposure through differential regulation of the MAPK signal transduction pathway. 4. Schisandrol B significantly inhibits cell proliferation in a dose-dependent manner, due to cell cycle arrest in the G1 phase with the downregulation of cyclin D1 expression and Retinoblastoma (RB) phosphorylation.

YX-2-107 is a selective and potent CDK6-degrading PROTAC with an IC50 value of 4.4 nM.YX-2-107 inhibits RB phosphorylation and FOXM1 expression in vitro, and inhibits the development of Ph+ ALL in rats.YX-2-107 can be used for the prophylaxis and treatment of Ph chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). YX-2-107 can be used for the prevention and treatment of Ph chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).

Schisandrol B (Standard) is a reference standard for research and analysis in studies involving Schisandrol B. 1. Schisandrol B (Besigomsin) may exert neuroprotective effects by attenuating the microglia-mediated neuroinflammatory response via inhibiting the TLR4-mediated NF-κB and MAPKs signaling pathways. 2. Schisandrol B has anti-inflammatory property, potentially result from the inhibition of COX-2, iNOS, IL-6, TNF-α and NO through the down-regulation of RIP2 and NF-κB activation. 3. Schisandrol B induces marked protective effects against hepatic and renal injury induced by CCl(4) exposure through differential regulation of the MAPK signal transduction pathway. 4. Schisandrol B significantly inhibits cell proliferation in a dose-dependent manner, due to cell cycle arrest in the G1 phase with the downregulation of cyclin D1 expression and Retinoblastoma (RB) phosphorylation.

Endothelin-2 (49-69), human (Human endothelin-2), is a 21-amino-acid vasoactive peptide that binds to G-protein-coupled receptors ET-RA and ET-RB.

Endothelin-2 (49-69), human (TFA), is a 21-amino acid vasoactive peptide that binds to ET-RA and ET-RB receptors.